Share
Save
Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.
Study details:
Intensive care patients face health issues that extend beyond their critical illness. A specific area where critical illness may adversely affect the well-being of survivors is increased bone turnover during critical illness, and accelerated bone loss in subsequent years. Critical illness bone loss begins in the first days of critical illness, occurs in both men and women, and is greatest in post-menopausal women.
Loss of bone mineral density is significantly greater at both the femur (-2+4. 0% vs -0. 7+1.
1%, p=0. 001) and spine (-2. 9+4.
1% vs -0. 2+1. 1%, p\<0.
001) in women in the year after critical illness compared to age-matched controls. One year after critical illness, 80% of women aged 50-years or greater are classified as osteoporotic or osteopaenic, compared to 71% of the approximately 3. 7 million Australian women aged 50 year or greater.
In the year after ICU admission a decrease in femur BMD of -1. 52% (+ 2. 85) is reported in men, which is significantly higher than age adjusted population controls (-0.
42% + 1. 13, diff -1. 10% (95% CI -1.
71 to -0. 49, p\<0. 001).
The annual incidence of first fracture in men aged 70 years and over is similar to the annual incidence of fracture in women aged 50 years and over. In addition, there is a dramatic increase in hip fractures as a proportion of all fracture's males aged 70 years and older in the general population. This population is most likely to suffer the major consequence of accelerated bone loss, fragility fracture, and the associated morbidity, loss of quality of life, and economic cost.
Older women who survive critical illness have a significantly higher fragility fracture rate compared to community age-matched controls (Intensive Care Unit 4. 33 vs control 2. 81 per 100 patient years, adj HR 1.
7 (95% CI 1. 1-2. 5), p=0.
02). Bone antiresorptive therapies are effective at reducing bone loss and decreasing fracture risk in non-critically ill populations. Zoledronic acid and denosumab represent antiresorptive agents with established efficacy in adults, and are potential target interventions able to be delivered during critical illness.
Denosumab is a human monoclonal antibody directed against Receptor activator of nuclear factor kappa-Β ligand, a central stimulator of osteoclast activity, and is effective for prevention of fractures and bone loss in osteoporosis and malignancy. Zoledronic acid is a bisphosphonate class agent that binds to bone and suppresses bone resorption by entering osteoclasts and inhibiting the enzyme farnesyl pyrophosphate synthase, resulting in disruption of osteoclast attachment to bone surface. In addition to skeletal effects, there are possible mortality benefits associated with the use of antiresorptive medications in populations with increased bone loss.
There is currently insufficient high-quality evidence to support routine, early use of antiresorptive medications in critically ill adults. The Bone Zone trial is a phase III multi-centre randomised placebo-controlled trial of 450 women aged 50-years or greater and men aged 70-years or greater requiring intensive care admission for more than 2 calendar days, to determine the effect of denosumab or zoledronic acid on the prevention of bone loss in the year after critical illness.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 50 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2021-07-15
Primary completion: 2027-02-28
Study completion finish: 2027-02-28
Study type
TREATMENT
Phase
PHASE2
Trial ID
NCT04608630
Intervention or treatment
DRUG: Denosumab 60 MG/ML
DRUG: Zoledronic Acid 5Mg/Bag 100Ml Inj
DRUG: Sodium Chloride 0.9% or 5% Dextrose Intravenous
DRUG: Sodium Chloride 0.9% Injection
Conditions
- • Critical Illness
- • Osteoporosis
Find a site
Closest Location:
Gold Coast University Hospital
Research sites nearby
Select from list below to view details:
Gold Coast University Hospital
Southport, Queensland, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Alfred Health
Melbourne, Victoria, Australia
John Hunter Hospital
Newcastle, New South Wales, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Participant Group/Arm | Intervention/Treatment |
---|---|
ACTIVE_COMPARATOR: Denosumab
| DRUG: Denosumab 60 MG/ML
|
ACTIVE_COMPARATOR: Zoledronic acid
| DRUG: Zoledronic Acid 5Mg/Bag 100Ml Inj
|
PLACEBO_COMPARATOR: Placebo
| DRUG: Sodium Chloride 0.9% or 5% Dextrose Intravenous
|
What is the study measuring?
Primary outcome
Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
---|---|---|
Annualised change in femoral neck bone mineral density for the year after Intensive Care discharge | Change in femoral neck bone mineral density T-score between baseline and 12 months | 12 months |
Secondary outcome
Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
---|---|---|
Annualised change in lumbar spine bone mineral density for the year after Intensive Care discharge | Change in lumbar spine bone mineral densityT-score between baseline and 12 months | 12 months |
Clinical fragility fracture | Self-reported incident clinical fractures obtained at follow-up visits. Information on the date, site, and circumstance of the fracture obtained by interview and X-ray report sought and confirmed by medical report. | 6 and 12 months |
Vertebral fracture | Incident vertebral fracture obtained during lateral BMD study | 12 months |
Falls | Self-reported falls incidence and frequency | 6 and 12 months |
Hospital readmission | All hospital readmissions within 12 months will be recorded | 12 months |
Mortality | All deaths from enrolment to 12 months will be recorded | 12 months |
Change in quality of life | Quality of life will be measured using the European Quality of Life scale using a descriptive system scale from 1 to 5 | 0, 6 and 12 months. |
Bone turnover outcomes (nested sub-study) | Change in the bone turnover markers serum collagen type 1 cross-linked c-telopeptide (CTX), and serum type 1 procollagen N-terminal propeptide (P1NP) | Day 0, Day 7, 6 and 12 months |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!